Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Knight Therapeutics secured Brazilian approval for an expanded indication of MINJUVI (tafasitamab), a lymphoma therapy partnered with Incyte.
The company also filed for the same new indication in Argentina and Mexico, beginning broader Latin American regulatory outreach.
These steps represent the first approvals and filings for MINJUVI’s new use in the region and add treatment options for lymphoma patients.
The development highlights progress in Incyte’s international oncology pipeline outside its core U.S. and EU markets.
For investors tracking Incyte (NasdaqGS:INCY), this MINJUVI update is another piece of the story, alongside a current share price of $94.22 and a 57.0% return over the past year. The company has also recorded returns of 28.2% over three years and 18.0% over five years, which provides useful context as it moves further into international markets.
Expanded MINJUVI activity in Latin America reflects a broader footprint for Incyte-partnered assets and a more diversified geographic mix over time. Investors may want to monitor how additional approvals and uptake in these new indications progress, given the focus on oncology and late-stage assets outside the U.S. and EU.
Stay updated on the most important news stories for Incyte by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Incyte.
NasdaqGS:INCY Earnings & Revenue Growth as at Mar 2026
📰 Beyond the headline: 2 risks and 3 things going right for Incyte that every investor should see.
This MINJUVI update adds another partnership-driven piece to Incyte’s effort to broaden its oncology reach beyond core territories. Knight Therapeutics already distributes MINJUVI in Latin America for diffuse large B-cell lymphoma, so the new Brazilian indication in follicular lymphoma and filings in Argentina and Mexico extend an existing commercial platform rather than starting from scratch. For Incyte, this type of regional agreement can widen exposure to lymphoma markets without the fixed costs of building its own local infrastructure, while Knight handles country-specific execution and regulatory follow-up. Against the backdrop of Zynyz’s recent European approval and the FDA Complete Response Letter tied to a third-party facility, MINJUVI’s Latin American steps show how partnerships can diversify both products and geographies. Investors focusing on Incyte’s goal of reducing reliance on Jakafi may see this as incremental support for that plan, although the scale and timing of MINJUVI uptake in these markets remains an open question. It also illustrates how Incyte is using regional collaborators to extend late-stage assets, a theme that could matter more as additional oncology indications progress.
The MINJUVI expansion aligns with the narrative that new launches and label extensions in oncology can support more diversified revenue sources over time.
At the same time, reliance on partners such as Knight Therapeutics adds another layer of execution risk alongside existing regulatory and manufacturing uncertainties around products like Zynyz.
The narrative focuses heavily on larger markets and key assets such as Opzelura and Zynyz, so Latin American MINJUVI progress may not be fully reflected in expectations around international uptake.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Incyte to help decide what it’s worth to you.
⚠️ Analysts have flagged 2 key risks for Incyte, including expectations that earnings could decline on average over the next 3 years, which may limit how much minor partnership wins can influence the overall story.
⚠️ Execution in Latin America depends on Knight’s regulatory and commercial performance, so slower-than-expected uptake or pricing pressure could reduce the impact of these MINJUVI indications.
🎁 Incyte trades on a P/E of 14.6x, below the wider US market at 18.4x, which some investors may see as room for sentiment to improve if international oncology efforts continue to build.
🎁 Earnings grew by a very large amount over the past year and the company is viewed as trading at good value compared with peers and its industry, which may support investors who want exposure to a broader late-stage pipeline.
From here, the key items to watch are the approval decisions in Argentina and Mexico, the pace of physician adoption for MINJUVI’s new indication in Brazil, and any commentary from Incyte or Knight on real-world demand. It is also useful to track how this Latin American progress sits alongside further regulatory milestones for Zynyz and other late-stage assets, given the focus on building non-Jakafi revenue. Any updates on additional partnership agreements or expanded indications for MINJUVI could help clarify how meaningful this collaboration becomes in the wider oncology portfolio.
To ensure you’re always in the loop on how the latest news impacts the investment narrative for Incyte, head to the community page for Incyte to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include INCY.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com